No Data
InMed Pharmaceuticals Explores CBN for Skin Disease Treatment
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
InMed Pharmaceuticals | 8-K: InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Pharmaceuticals Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q4 EPS Results.
InMed Pharmaceuticals GAAP EPS of -$2.17, Revenue of $1.26M
Earnings Flash (INM) INMED PHARMACEUTICALS Reports Q1 Revenue $1.3M
No Data